Monday, June 15, 2026

Eli Lilly’s New Weight Loss Pill Foundayo: A Game Changer in the GLP-1 Market?

The FDA has approved Eli Lilly's oral obesity drug Foundayo, enhancing competition in the weight loss market with flexible dosing.

Luxury Heist in Gangnam: American Man Caught Stealing 15 Million KRW Worth of Designer Goods

A U.S. citizen was arrested in Seoul for stealing luxury items from a department store, attempting theft twice on the same day.

Korea University Enters Top 6 at the 2026 VCIC Global Finals

A Korean team reached the Top 6 at the VCIC Global Final, showcasing talent in venture investment and highlighting government support.

Tag: obesity

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Can GLP-1 Medications Reduce Breast Cancer Risk? New Research Reveals Surprising Findings

GLP-1 drugs show promise in cancer prevention and progression inhibition, expanding beyond obesity treatment to chronic disease management.

AstraZeneca’s Elecoglipron: Can This New Weight Loss Pill Compete with GLP-1 Giants?

AstraZeneca's new weight-loss pill, elecoglipron, shows promising results in trials, competing with existing obesity treatments.

Inventage Lab Secures Patent for Semaglutide Formulation Aimed at Improving Oral Bioavailability

Inventage Lab secures a patent for a liposome formulation enhancing semaglutide's bioavailability, aiming to lead in obesity treatment.

Novo Nordisk’s Oral Wegovy Just Put Up a Number That Could Change the Obesity Drug Race

Novo Nordisk's oral obesity treatment, Wegovy, saw $400M in Q1 2026 sales, exceeding estimates and indicating strong market demand.

D&D Pharmatech signs $1.24 million obesity drug research deal with Pfizer

D&D Pharmatech partners with Pfizer for a $1.24M obesity treatment project, marking a significant revenue milestone for the company.

Unlocking Weight Loss: How GB102 Probiotics Enhance GLP-1 Obesity Drugs

GI Longevity's GB102 probiotic enhances weight loss with GLP-1 medications, reducing rebound gain and improving blood sugar control.

JW Pharmaceuticals Secures Exclusive Rights for Innovative GLP-1 Drug Vopaglutide in South Korea

JW Pharmaceutical secures exclusive rights for Vopaglutide, a promising treatment for diabetes and obesity, with significant milestone payments.

Sam Chun Dang Pharm Signs 100 Million USD Licensing Deal for Oral Generics of Rybelsus and Wegovy

Sam Chun Dang Pharm secures a U.S. licensing deal for generic diabetes and obesity medications, valued at $100 million.

Inventage Lab Secures 985 Billion KRW: What This Means for Long-Lasting Injection Solutions

Inventage Lab secures 985 billion KRW to enhance its drug delivery platform, focusing on long-acting injectables for obesity and more.

GLP-1 Weight Loss Injections: Are They Causing Gallstone Surge in Asia?

GLP-1 obesity treatments are linked to increased gallstone risk, especially during rapid weight loss, with cases doubling in South Korea.

Novo Nordisk Slashes GLP-1 Drug Prices by Up to 50%: What This Means for Obesity Treatments in 2027

Novo Nordisk will cut prices of GLP-1 treatments in the U.S. by up to 50% from January 2027, amid rising competition and market pressures.

Hanmi Posts Record $1.16B Sales and $193M Operating Profit: What’s Driving the 2025 Surge

Hanmi Pharmaceutical reports record sales of $1.16 billion in January 2025, with significant growth in profits and new product launches.

How a 2-Cent Sugar Tax Could Save $4.5 Billion in Healthcare Costs: California’s Bold Move

A sugar-sweetened beverage tax in California could cut obesity cases and save $4.5 billion in healthcare costs over ten years.

Chinese Biotech’s Rise: What’s the Standard of Global Tech Trade?

Analysts at the JPMHC noted a shift in biotech, with firms resisting sales and China emerging as a tech transfer leader.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.